Education
About Us
Working with TipRanks
Follow Us
Sinopharm Tech Holdings Limited (HK:8156)
:8156
Top Page
Sinopharm Tech Holdings Limited
(8156)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.31
▲(39.55% Upside)
The overall stock score is primarily impacted by financial performance challenges, including negative equity and profitability issues. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth Momentum
A >200% annual revenue surge indicates strong product demand or market re-entry, expanding the addressable base. Sustained top-line growth supports operating leverage, funds reinvestment and scale benefits, and materially improves the odds of durable margin recovery if maintained.
Improving Free Cash Flow
Material improvement in free cash flow implies the business is moving toward internal funding capacity. Over the medium term this reduces reliance on external financing, enables debt paydown or strategic reinvestment, and strengthens liquidity if improvement persists.
Lean Operating Base
A very small headcount is consistent with a scalable software/application model and lower fixed cost structure. If revenue growth continues, incremental sales can flow to operating profit more quickly, enabling faster margin expansion and capital efficiency.
Negative Factors
Negative Equity & High Leverage
Negative equity and heavy leverage are structural constraints: they limit financing options, increase default and covenant risk, and impair the firm's ability to fund growth or weather shocks. Restoring equity or deleveraging is a multi-quarter structural requirement.
Negative Operating Cash Flow
Persistently negative operating cash flow undermines self-sufficiency and forces reliance on external financing or asset sales. Over months this can constrain working capital, hamper product investment, and raise refinancing risk, especially given the company’s leverage profile.
Sustained Unprofitability
Negative EBIT and net margins reflect structural cost or pricing issues; without durable margin improvement the company will struggle to convert revenue into shareholder value. Continued losses erode equity, limit reinvestment capacity and prolong financing needs.
Sinopharm Tech Holdings Limited (8156) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$196.44M
Dividend YieldN/A
Average Volume (3M)157.92K
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue Growth48.39%
EPS Growth88.30%
CountryHK
Employees30
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)N/A
Shares Outstanding633,693,050
10 Day Avg. Volume46,340
30 Day Avg. Volume157,918
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)-2.33
Price to Sales (P/S)1.40
P/FCF Ratio-11.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Tech Holdings Limited Business Overview & Revenue Model
Company DescriptionSinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People's Republic of China and Hong Kong. The company operates through Provision of Lottery-Related Services, Provision of Internet Plus Services, Manufacturing and Distribution of Personal Protective Equipment, and Other Services segments. It offers lottery-related hardware and software systems. The company is also involved in the provision of Internet plus solution services to health care, government affairs, leasing, public security, and other industries; and supply chain management, data analysis, and related services, as well as trading of goods through internet platform. In addition, it offers corporate management services; and distribution of personal protective equipment. The company was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. Sinopharm Tech Holdings Limited was founded in 1999 and is headquartered in Sha Tin, Hong Kong.
How the Company Makes MoneySinopharm Tech Holdings Limited generates revenue through multiple streams, primarily from the sale of pharmaceutical products, medical devices, and healthcare solutions. The company partners with various healthcare institutions and organizations to provide integrated healthcare services and products, which contribute significantly to its income. Additionally, Sinopharm Tech engages in research and development activities, often collaborating with universities and research institutions to innovate new products. Revenue is also bolstered by government contracts and grants aimed at improving public health infrastructure, as well as strategic partnerships with other technology firms in the health sector.
Sinopharm Tech Holdings Limited Financial Statement Overview
Summary
Sinopharm Tech Holdings Limited is experiencing strong revenue growth but faces significant profitability and financial stability challenges. The negative equity and high leverage are major concerns, while cash flow improvements offer some hope for recovery.Income Statement
The company has shown significant revenue growth of 224.12% in the latest year, indicating a strong recovery. However, profitability remains a concern with a negative net profit margin and EBIT margin, reflecting ongoing operational challenges.45
Neutral
Balance Sheet
The balance sheet reveals a negative stockholders' equity, indicating financial instability. The high debt-to-equity ratio suggests significant leverage, posing a risk to financial health. The return on equity is not meaningful due to negative equity.30
Negative
Cash Flow
Cash flow from operations is negative, which is concerning. However, there is a substantial improvement in free cash flow growth, suggesting potential for future cash generation. The ratios indicate cash flow challenges relative to net income.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.25M | 61.25M | 41.28M | 42.84M | 40.98M | 77.81M |
| Gross Profit | 14.23M | 13.52M | 5.02M | 5.47M | 5.10M | 20.88M |
| EBITDA | 6.11M | 6.11M | 4.98M | -1.01M | -75.17M | -89.65M |
| Net Income | -867.00K | -867.00K | -19.70M | -10.63M | -88.00M | -106.34M |
Balance Sheet | ||||||
| Total Assets | 51.74M | 51.74M | 44.49M | 33.48M | 76.89M | 135.90M |
| Cash, Cash Equivalents and Short-Term Investments | 6.95M | 6.95M | 2.64M | 1.78M | 2.99M | 7.48M |
| Total Debt | 46.73M | 46.73M | 73.26M | 53.00M | 45.93M | 108.03M |
| Total Liabilities | 88.43M | 88.43M | 250.09M | 213.24M | 250.28M | 276.46M |
| Stockholders Equity | -36.87M | -36.87M | -199.48M | -172.73M | -166.78M | -138.88M |
Cash Flow | ||||||
| Free Cash Flow | -781.00K | -7.21M | -12.58M | 4.73M | -36.88M | -16.32M |
| Operating Cash Flow | -5.69M | -7.21M | -9.25M | 4.73M | -36.76M | -6.21M |
| Investing Cash Flow | -9.00K | -9.00K | -4.86M | 2.00K | -85.00K | -5.05M |
| Financing Cash Flow | 9.98M | 11.50M | 14.98M | -4.52M | 32.24M | 12.46M |
Sinopharm Tech Holdings Limited Technical Analysis
Positive
0.22
Price Trends
0.32
Negative
0.29
Positive
0.24
Positive
Market Momentum
>-0.01
Positive
47.68
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.32, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.68 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8156.
Sinopharm Tech Holdings Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$148.89M | -31.90 | -2.72% | 0.57% | -13.40% | 76.97% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
48 Neutral | HK$196.44M | -24.22 | ― | ― | 48.39% | 88.30% | |
47 Neutral | HK$117.15M | -14.71 | -97.49% | ― | -49.86% | 15.00% | |
46 Neutral | HK$32.41M | -145.00 | -0.42% | ― | -14.25% | 77.78% | |
44 Neutral | HK$54.54M | -9.89 | -523.99% | ― | 78.40% | 72.37% | |
44 Neutral | HK$48.00M | -40.00 | -2.07% | ― | -6.88% | -100.00% |
* Technology Sector Average
HK:8156
Sinopharm Tech Holdings Limited
0.31
0.21
210.00%
HK:8071
China Netcom Technology Holdings Limited
0.03
<0.01
25.00%
HK:8036
eBroker Group Limited
0.03
-0.01
-30.95%
HK:8100
GET Holdings Limited
0.34
0.21
157.69%
HK:8131
abc Multiactive Limited
0.09
0.02
30.00%
HK:8290
Ahsay Backup Software Development Company Limited
0.02
<0.01
20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.